Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
| Autor: | Matthew Guo, Andrew G. Gianoukakis, N. Batty, Corina E. Dutcus, Mahadi Ali Baig |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
medicine.medical_specialty radioiodine-refractory differentiated thyroid carcinoma Phases of clinical research lenvatinib Placebo Gastroenterology chemistry.chemical_compound select Internal medicine Medicine Pharmacology (medical) Radiology Nuclear Medicine and imaging In patient Objective response Thyroid cancer duration of response RC254-282 business.industry Hazard ratio Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Confidence interval Oncology Otorhinolaryngology chemistry Surgery business Lenvatinib |
| Zdroj: | Opuholi Golovy i Šei, Vol 8, Iss 3, Pp 53-60 (2018) |
| ISSN: | 2411-4634 2222-1468 |
| Popis: | We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled phase 3 study, patients ≥18 years old with measurable, pathologically confirmed RR-DTC with independent radiologic confirmation of disease progression within the previous 13 months were randomized 2:1 to oral lenvatinib 24 mg/day or placebo. The main outcome measures for this analysis are DOR and progression-free survival (PFS). The median DOR for all lenvatinib responders (patients with complete or partial responses; objective response rate: 60.2 %; 95 % confidence interval (CI) 54.2–66.1) was 30.0 months (95 % CI 18.4–36.7) and was generally similar across subgroups. DOR was shorter in patients with greater disease burden and with brain and liver metastases. Updated median PFS was longer in the overall lenvatinib group vs placebo (19.4 vs 3.7 months; hazard ratio (HR) 0.24; 99 % CI 0.17–0.35; nominal P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|